Lecanemab is a medicine for people in the early stages of Alzheimer's disease. It is given as an infusion into a vein, or as a shot under the skin. It works by helping the body clear away a sticky protein called amyloid that builds up in the brain.
Every report comes from a Lived member, sent anonymously.
Have you tried Leqembi (Lecanemab) for Alzheimer's?
Lecanemab, sold as Leqembi, is a prescription treatment for Alzheimer's disease in its early stages: mild cognitive impairment (memory or thinking problems that are noticeable but do not yet stop a person managing daily life) or mild dementia. It is started only at these stages, because that is the group it was tested in. It is not a treatment for moderate or advanced dementia, and it has not been studied in children. Before starting, the care team has to confirm that amyloid, the protein that builds up in the brain in Alzheimer's disease, is actually present. In the main trial this was done with a PET (positron emission tomography) scan, which can show amyloid deposits in the brain, or a spinal fluid test. Memory problems from other causes do not qualify. Leqembi is given either as an infusion into a vein at a clinic or as a weekly injection under the skin with an autoinjector called Leqembi Iqlik. Kisunla (donanemab) is a similar antibody treatment for the same early stage. In the main trials, people could keep taking older Alzheimer's medicines that ease symptoms, such as cholinesterase inhibitors (for example donepezil, sold as Aricept) and memantine, alongside lecanemab.
In Alzheimer's disease, a protein called amyloid beta clumps together in the brain, first into small floating clusters and then into larger deposits called plaques. This buildup is a defining feature of the disease and may start or speed up the damage to brain cells that gradually affects memory, thinking and independence. Lecanemab is a monoclonal antibody, a laboratory-made immune protein designed to recognize one specific target. It attaches to clumped forms of amyloid beta, both the smaller clusters and the plaques, and helps the body clear them. In the trials, brain scans showed large drops in amyloid over 18 months. Clearing amyloid is linked to slower decline on average, but it does not stop the disease or repair damage that has already happened.
The infusion form is given through a vein in the arm at an infusion center. Each infusion takes about an hour, it is given every two weeks, and the dose is based on body weight. The Leqembi Iqlik autoinjector is a weekly injection under the skin of the thigh or abdomen; the starting dose is two injections given together. At least the first two injections are given under a clinician's direct supervision. After that, the clinician may decide the person or a caregiver can inject at home, which includes being able to recognize and respond to a serious allergic reaction. After 18 months, the person can stay on the same schedule or move to a maintenance schedule: infusions every four weeks, or a smaller weekly injection. People can also switch between infusions and injections. There is limited evidence on how well the maintenance schedules preserve benefit over the long term. Brain MRI (magnetic resonance imaging) scans are part of the treatment itself. A recent MRI is needed before the first dose, and further scans follow after about 1, 2, 3 and 6 months, each reviewed before the next dose is given. If an infusion is missed, it should be rescheduled as soon as possible. A missed injection can be given up to 6 days late, then the usual weekly day resumes.
With the infusion, reactions during or after the infusion are the most common side effect, affecting about a quarter of people in the main trial, mostly with the first dose. They can feel like flu, with fever, chills, body aches or shakiness, and can also bring nausea, vomiting, dizziness, a pounding heart or changes in blood pressure. Most are mild or moderate, and they can start after the person has left the infusion center. Tell the care team right away; medicines such as antihistamines, acetaminophen or steroids before later infusions can lower the chance of another reaction. With the injection, redness, swelling, pain, itching or bruising at the injection site are common, sometimes appearing a few days later, along with headache, chills or tiredness. Headache is also common with either form. The most important risk is ARIA, short for amyloid-related imaging abnormalities. It means temporary swelling in areas of the brain, sometimes with small spots of bleeding or iron deposits in or on the surface of the brain. It usually appears in the first months of treatment, is mostly found on the scheduled MRIs, and usually causes no symptoms. In the main trial, about 1 in 5 people on lecanemab had ARIA of some kind, compared with about 1 in 11 on placebo; 3% had symptoms, and fewer than 1% had serious symptoms. The swelling cleared on later scans in every case, mostly within about four months. Rarely, ARIA is severe, causes seizures or is fatal, and larger bleeds in the brain occurred in 0.7% of people on lecanemab compared with 0.1% on placebo. Because ARIA can feel like an ordinary side effect, what matters is a change. Confusion, vision changes, dizziness or unsteadiness, difficulty walking, or a headache that is new, worsening or does not go away (with or without nausea) can be signs of ARIA, most often in the first months. Call the prescriber or go to the nearest emergency room right away; an MRI may be needed before the next dose. A seizure, sudden weakness or trouble speaking, or a sudden severe headache needs a 911 call, and responders should be told about the lecanemab treatment. Swelling of the face, lips, mouth or tongue, hives, or trouble breathing during or after a dose may be a serious allergic reaction and needs medical help right away.
Before starting, prescribers recommend a genetic test for ApoE4, a common variant of a gene linked to Alzheimer's risk. People with two copies of ApoE4 (about 15% of people with Alzheimer's) have a much higher chance of ARIA: in the main trial, 9% of them had ARIA swelling with symptoms, compared with 2% of people with one copy and 1% of those with none. In this group the trial also did not show a slowing of decline on its main measure. The prescriber should discuss what the result could mean before testing. A person can decline the test and still be treated, but then their level of risk is unknown. Some findings on the first MRI, such as several earlier small bleeds or areas of iron deposits, also raise the risk of ARIA and brain bleeding and call for extra caution. Blood thinners matter. In the main trial, people taking an anticoagulant (a blood thinner such as warfarin or apixaban) had more large brain bleeds with lecanemab, and the label advises caution with aspirin and other antiplatelet medicines too. Tell the prescriber about all of them, including over-the-counter aspirin, and ask before starting or stopping one. ARIA can cause sudden weakness or other symptoms that look like a stroke. Clot-dissolving drugs used for stroke have led to a fatal brain bleed in a person taking this type of antibody, so emergency doctors need to know about the treatment before giving one. Carry a card or note saying you receive lecanemab. People who have had a serious allergic reaction to lecanemab should not receive it again. There is too little information to know whether it is safe during pregnancy or breastfeeding.
Lecanemab slows decline; it does not stop Alzheimer's disease or bring back lost memory or skills. The main trial measured change on an 18-point rating of memory, judgment and everyday function, where a higher score means more impairment. Over 18 months, people on lecanemab worsened by about 1.2 points and people on placebo by about 1.7, roughly 27% less decline. Scores for thinking and for daily activities also declined less, and the difference between groups was measurable from about six months on. Experts describe the average benefit as modest, and how much difference it makes in one person's daily life varies. The first months are the most demanding: frequent infusions or weekly injections, several MRIs and the closest watch for ARIA, especially in the first 14 weeks. ARIA can still happen later, and some people have it more than once. If a scan shows ARIA, doses may be paused until the scans improve, and the prescriber decides whether to resume or stop. After 18 months, the person and prescriber decide whether to continue on the same schedule or switch to maintenance dosing. The treatment also involves practical commitments, including travel to appointments and scans, cost and insurance questions, and often a caregiver's time and help watching for symptoms. These are reasonable parts of deciding whether it is worth starting.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Leqembi (Lecanemab), what you've noticed, or ask the community a question.